JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: CCT128930 is a novel, potent, ATP-competitive and selective pyrrolopyrimidine-based inhibitor of Akt2 (IC50 = 6 nM in a cell-free assay) with potential anticancer activity. It showed 28-fold greater selectivity for Akt2 over the closely related PKA kinases. CCT128930 was discovered through fragment- and structure-based drug design approaches. CCT128930 exhibited marked antiproliferative activity and inhibited the phosphorylation of a range of AKT substrates in multiple tumor cell lines in vitro, consistent with AKT inhibition. In conclusion, CCT128930 is a novel, potent and selective AKT inhibitorthat blocks AKT activity in vitro and in vivo and induces markedantitumor responses.
References: Mol Cancer Ther. 2011 Feb; 10(2):360-71.
Synonym: CCT128930; CCT-128930; CCT 128930.
Chemical Name: 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2, 3-d]pyrimidin-4-yl)piperidin-4-amine
SMILES Code: NC1(CC2=CC=C(Cl)C=C2)CCN(C3=C4C(NC=C4)=NC=N3)CC1
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!